Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma

Oncology Letters

Volumn 6, Issue 6, 2013, Pages 1707-1712

  Weng, Zhihong ^a,b   Ertle, Judith ^a   Zheng, Shaoping ^b   Lauenstein, Thomas ^a   Mueller, Stefan ^a   Bockisch, Andreas ^a   Gerken, Guido ^a   Yang, Dongliang ^b   Schlaak, Joerg F ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Choi criteria; Hepatocellular carcinoma; mRECIST; RECIST; Transarterial radioembolization; Tumor response

Indexed keywords

YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURVIVAL; CELL DENSITY; CHOI RESPONSE CRITERIA; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TRANSARTERIAL RADIOEMBOLIZATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

EID: 84886790456     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1612     Document Type: Article

References (17)

1. Bruix J and Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022, 2011.
2. Jelic S and Sotiropoulos GC; ESMO Guidelines Working Group: Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5): v59-v64, 2010.
3. Kennedy A, Coldwell D, Sangro B, Wasan H and Salem R: Integrating radioembolization (90)Y microspheres) into current treatment options for liver tumors: introduction to the international working group report. Am J Clin Oncol 35: 81-90, 2012.
4. Sangro B, Iñarrairaegui M and Bilbao JI: Radioembolization for hepatocellular carcinoma. J Hepatol 56: 464-473, 2012.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
6. Lencioni R and Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52-60, 2010.
7. Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25: 1753-1759, 2007.
8. Hamami ME, Poeppel TD, Müller S, Heusner T, Bockisch A, Hilgard P and Antoch G: SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med 50: 688-692, 2009.
9. Nathan PD, Vinayan A, Stott D, Juttla J and Goh V: CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 9: 15-19, 2010.
10. Smith AD, Lieber ML and Shah SN: Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 194: 157-165, 2010.
11. Llovet JM, Di Bisceglie AM, Bruix J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711, 2008.
12. Merine D, Takayasu K and Wakao F: Detection of hepatocellular carcinoma: comparison of CT during arterial portography with CT after intraarterial injection of iodized oil. Radiology 175: 707-710, 1990.
13. Fujita M, Kuroda C, Kumatani T, et al: Comparison between conventional and spiral CT in patients with hypervascular hepatocellular carcinoma. Eur J Radiol 18: 134-136, 1994.
14. Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739, 2002.
15. Riaz A, Miller FH, Kulik LM, et al: Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 303: 1062-1069, 2010.
16. Goh V, Halligan S, Gharpuray A, Wellsted D, Sundin J and Bartram CI: Quantitative assessment of colorectal cancer tumor vascular parameters by using perfusion CT: influence of tumor region of interest. Radiology 247: 726-732, 2008.
17. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB and Boven E: Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer 102: 803-809, 2010.